HCV viral decline at week 2 of Peg-IFN-alpha-2a/RBV therapy as a predictive tool for tailoring treatment in HIV/HCV genotype 1 co-infected patients.
about
HCV viral decline at week 2 of Peg-IFN-alpha-2a/RBV therapy as a predictive tool for tailoring treatment in HIV/HCV genotype 1 co-infected patients.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
HCV viral decline at week 2 of ...... notype 1 co-infected patients.
@ast
HCV viral decline at week 2 of ...... notype 1 co-infected patients.
@en
type
label
HCV viral decline at week 2 of ...... notype 1 co-infected patients.
@ast
HCV viral decline at week 2 of ...... notype 1 co-infected patients.
@en
prefLabel
HCV viral decline at week 2 of ...... notype 1 co-infected patients.
@ast
HCV viral decline at week 2 of ...... notype 1 co-infected patients.
@en
P2093
P2860
P50
P1433
P1476
HCV viral decline at week 2 of ...... enotype 1 co-infected patients
@en
P2093
Almudena Torres-Cornejo
Ana Gordon
Angela Camacho
Julian Torre-Cisneros
Pompeyo Viciana
Rosa Ruiz-Valderas
P2860
P304
P356
10.1371/JOURNAL.PONE.0099468
P407
P577
2014-06-19T00:00:00Z